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Adult hippocampal neurogenesis is stimulated by
chronic administration of antidepressants (ADs) and
by voluntary exercise. Neural progenitor cells (NPCs)
in the dentate gyrus (DG) that are capable of continu-
ous proliferation and neuronal differentiation are the
source of such structural plasticity. Here we report
that mice lacking the receptor tyrosine kinase TrkB
in hippocampal NPCs have impaired proliferation
and neurogenesis. When exposed to chronic ADs or
wheel-running, no increase in proliferation or neuro-
genesis is observed. Ablation of TrkB also renders
these mice behaviorally insensitive to antidepressive
treatment in depression- and anxiety-like paradigms.
In contrast, mice lacking TrkB only in differentiated
DG neurons display typical neurogenesis and re-
spond normally to chronic ADs. Thus, our data estab-
lish an essential cell-autonomous role for TrkB in reg-
ulating hippocampal neurogenesis and behavioral
sensitivity to antidepressive treatments, and support
the notion that impairment of the neurogenic niche is
an etiological factor for refractory responses to an
antidepressive regimen.
INTRODUCTION
Depression is a significant public health problem due to both its
high prevalence and its devastating impact on individuals and
society. Despite much excitement generated by recent ad-
vances in the knowledge of brain development and function,
the mechanisms underlying the pathogenesis of depression, as
well as its amelioration by antidepressant (AD) treatment, remain
poorly understood (Manji et al., 2001; Nestler et al., 2002). Clin-
ical studies demonstrate that 40% of depressed patients fail to
respond to first-line ADs and 70% do not undergo full remission
(Fagiolini and Kupfer, 2003; Thase and Rush, 1995). Such a vari-
able range of effectiveness underscores the heterogeneity of the
illness and the urgent need for thorough delineation of the cellu-
lar and molecular process involved in the action of ADs.As predicted by their pharmacological characteristics, most
ADs appear to act by increasing the activity of serotonergic
and noradrenergic circuits (Morilak and Frazer, 2004). However,
these medications usually require chronic administration for
weeks to months before clinically appreciable effects are
achieved. This represents an extended delay compared with
the rapid increase of serotonin and noradrenaline elicited by
these drugs (Frazer, 1997). Therefore, gradual yet essential
changes to the brain that occur during the period of delay appear
to be required for the response to ADs. Animal studies indicate
one such delayed response is the increased production of new
neurons in the dentate gyrus (DG) (Malberg et al., 2000; Perera
et al., 2007). Physical activity such as running, which is consid-
ered beneficial for mental health (Salmon, 2001), also induces in-
creased production of neurons (van Praag et al., 1999). Studies
in rodents have shown that upon exposure to chronic ADs or ex-
ercise, neural progenitor cells (NPCs) in the subgranular zone
(SGZ) of the DG undergo enhanced proliferation, which drives
the increase in neurogenesis (Encinas et al., 2006). Although
the functional significance remains to be proven, the positive as-
sociation of neurogenesis with ADs and exercise, aswell as other
beneficial stimulations such as diet, learning, and environmental
enrichment (Alvarez-Buylla, 1992; Kempermann et al., 1997; Lee
et al., 2000), implicates it as a physiologically relevant phenom-
enon. Indeed, irradiation-mediated ablation of proliferating cells
in the hippocampus compromises the ability of certain strains of
rodents to display a behavioral response to ADs, suggesting that
neurogenesis is an intrinsic requirement (Airan et al., 2007; Ho-
lick et al., 2008; Santarelli et al., 2003; Wang et al., 2008a). The
genetic mechanism underlying this observation remains unclear.
Coinciding with the elevation of neurogenesis, chronic AD ex-
posure elicits a variety of molecular adaptations (Tardito et al.,
2006). The mechanisms that link these molecular changes to
the biological effects of ADs are only beginning to be unveiled.
One of the molecules implicated is brain-derived neurotrophic
factor (BDNF), whose level in the hippocampus is increased by
chronic, but not acute, AD exposure (Nibuya et al., 1995). Infu-
sion of BDNF into the DG produces AD-like responses in several
behavioral paradigms (Shirayama et al., 2002). Mutant animals
with a global reduction of BDNF have a blunted response to
acute AD-induced behavioral changes (Monteggia et al., 2004;
Saarelainen et al., 2003). In humans, a single nucleotideNeuron 59, 399–412, August 14, 2008 ª2008 Elsevier Inc. 399
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TrkB Governs Sensitivity to Antidepressantspolymorphism of the BDNF gene (val66met) that interferes with
the activity-dependent secretion of BDNF protein has been as-
sociated with cognitive and structural abnormalities of the CNS
(Egan et al., 2003; Pezawas et al., 2004), though consensus is
lacking on its influence on susceptibility to mood disorders
(Choi et al., 2006; Jiang et al., 2005; Schule et al., 2006). Interest-
ingly, recent generation of mutant mice carrying the same poly-
morphism indicates a causative link between the genetic change
and elevated anxiety-like behaviors that are not normalized by
ADs (Chen et al., 2006). These observations, coupled with evi-
dence that exogenous BDNF promotes proliferation of hippo-
campal NPCs (Scharfman et al., 2005), suggest an important
role for BDNF in mediating the biological response to chronic
AD treatments (Wang et al., 2008b). Whether BDNF acts directly
on NPCs in vivo, andwhether its effects on NPCs then contribute
to the overall influence of BDNF on AD response, is unresolved.
In the present study, we conditionally ablated the gene encod-
ing TrkB, the high-affinity receptor for BDNF, in a regional- and
cell-type-specific manner. We show that NPC deletion of TrkB,
either in embryos or in the adult, results in impairment of hippo-
campal neurogenesis and prevents behavioral improvements
induced by chronic AD administration or wheel-running. In
contrast, deleting TrkB in differentiated neurons of the same
brain regions does not affect neurogenesis or the behavioral
responses to ADs. Our findings provide genetic evidence of
a functional, cell-autonomous requirement of TrkB in the neuro-
genic and behavioral responses to antidepressive treatments.
Furthermore, our results support the notion that DG NPCs are
a required component in the amelioration of depression (Zhao
et al., 2008).
Figure 1. TrkB Is Expressed by Hippocampal NPCs
(A) In situ hybridization analysis of TrkB and BDNF mRNA in
the adult dentate gyrus (DG). In the high-magnification image
(right), note the distribution of silver grains (black spheres) in
all cells. Scale bars, 1 mm (low-magnification) and 10 mm
(high-magnification). GL, granular layer; SGZ, subgranular
zone.
(B) Confocal image of the DG of an adult Nestin-GFP trans-
genic mouse, coimmunostained for GFP (green), NeuroD
(red), and NeuN (blue). GFP expression was restricted to
NPCs and did not colocalize with immature (NeuroD-positive)
or mature (NeuN-positive) neurons. Insert shows a DG-
derived neurosphere that expresses GFP. Scale bars, 10 mm.
(C) RT-PCR detection of TrkB and BDNF transcripts in
FACS-sorted Nestin-GFP-positive cells and DG-derived
neurospheres. NS, neurosphere.
(D) Immunostaining for TrkB (green) on adult DG sections
from wild-type and TrkBhGFAP mice (left panels). Costaining
for TrkB (green) and Ki67 (red) or Doublecortin (red) demon-
strated colocalization of TrkB with proliferating (Ki67-positive)
and differentiating (Doublecortin-positive) cells. Dcx,
Doublecortin; WT, wild-type. Scale bars, 10 mm and 5 mm.
RESULTS
TrkB Is Expressed by Hippocampal NPCs
We and others have previously demonstrated the
presence of TrkB transcripts and protein in the
hippocampus (Klein et al., 1990; Zhou et al., 1993). To deter-
mine whether transcripts are present in the neurogenic zone,
we first examined TrkB expression in the postnatal and adult
DG. In situ hybridization analysis showed prominent expression
of both BDNF and TrkB in the granular layer and SGZ of the DG
(Figure 1A). In particular, TrkB mRNA, represented by silver
bromide grains, was detectable throughout the cellular layers
of the DG (Figure 1A, right panel). To further examine whether
the DG NPCs express TrkB, we utilized Nestin-GFP transgenic
mice, in which GFP expression is confined to NPCs (Figure 1B)
(Yu et al., 2005). Using fluorescent-activated cell sorting
(FACS), GFP-positive cells from the DG of transgenic mice at
various ages were isolated, and analysis of these cells by
RT-PCR demonstrated the presence of NPC markers and
the absence of markers from the differentiated lineages
(Figure S1 available online). TrkB and BDNF mRNAs were de-
tected in the GFP-positive cells at all ages tested (postnatal
day [P] 2, 15 and 60, n = 3 animals for each, Figure 1C). Sim-
ilarly, TrkB and BDNF mRNAs were also detected in neuro-
spheres derived from the DG of adult wild-type mice (n = 3,
Figure 1C). We further analyzed the distribution of TrkB protein
in the progenitor population by coimmunostaining. Consistent
with its mRNA distribution, TrkB protein was detected in all
layers of the adult DG; confocal microscopy revealed its pres-
ence in both proliferating progenitors that are Ki67 positive
(86.2%, n = 160 cells from three animals) and immature
neurons that express Doublecortin (94.9%, n = 177 cells from
three animals) (Figure 1D). Taken together, our results demon-
strate the presence of TrkB mRNA and protein in hippocampal
NPCs.400 Neuron 59, 399–412, August 14, 2008 ª2008 Elsevier Inc.
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Germline homozygous TrkB knockout animals die shortly after
birth. To investigate the role of TrkB in postnatal stages, condi-
tional knockout animalswere generated by crossingmice harbor-
ing the TrkB flox alleles to transgenic mice expressing the Cre
recombinase either under the human GFAP (hGFAP) promoter
or the Synapsin I (Syn) promoter (He et al., 2004; Luikart et al.,
2005). In both the hGFAP-Cre and the Syn-Cre transgenic ani-
mals, the pattern of Cre expression allows recombination
throughout the forebrain, including cerebral cortex, hippocam-
pus, and olfactory bulb. In other regions of the brain, such as
themidbrain (dopaminergic neurons) andbrainstem (serotonergic
neurons), Cre expression is minimal (Figure S4 and not shown).
When these transgenic animals were interbred with Rosa26-
stop-lacZ reporter mice (R26) (Soriano, 1999) and analyzed at
the age of 2 months, a majority of the neurons in the aforemen-
tioned regions appeared to express functional beta-galactosi-
dase (b-gal) (Figure 2A and not shown). However, when such an-
imals were analyzed at a younger age (P10), a distinct anatomical
difference in the recombination patterns of the two Cre lines was
observed in theDG. In the R26hGFAP animalmost cells throughout
the DG expressed b-gal, whereas in the R26Syn animal, b-gal ex-
pressionwasconfined to theouter layers of theDG,while theSGZ
and inner granule layer, where NPCs and immature neurons
reside, were essentially spared of recombination (Figure 2A).
We next enriched NPCs from 2-month-old mice by culturing
primary cells from the DG in neurosphere-forming media
Figure 2. hGFAP-Cre, but Not Syn-Cre, Mediated
Recombination in Hippocampal NPCs
(A) X-gal staining on DG sections of R26hGFAP and R26Syn
mice at P10 and P60. Higher magnification views of the
boxed areas are shown in the right panels, in which black
lines outline the granular layer, while the red double arrow
highlights the SGZ and inner granular layer where recom-
bination was spared. Scale bars, 100 mm.
(B) Schematic diagram of the procedure to generate
neurospheres from adult DG.
(C) X-gal staining on primary neurospheres derived from
the DG of adult control, R26hGFAP, and R26Syn mice.
Blue staining in the neurosphere from R26hGFAP mice
indicated the occurrence of recombination. Scale bar,
100 mm.
(D) Western blots of lysates from the hippocampus of
control and TrkBhGFAP mice, probed for TrkB and actin.
Note the absence of TrkB in the TrkBhGFAP mice.
(E) RT-PCR detection of TrkB and G3PDH transcripts in
FACS-sorted Nestin-GFP-positive cells from the DG of
control and TrkBhGFAP mice. Note the absence of TrkB in
the TrkBhGFAP mice.
(Figure 2B). Upon X-gal staining, neurospheres
isolated from the DG of R26hGFAP mice, but not
those from the R26Syn or control mice, stained
positive for b-gal activity, indicating that recom-
bination only occurred in the hippocampal NPCs
from the R26hGFAP mice (Figure 2C). Thus, the
masking of X-gal staining difference in the adult
DG (Figure 2A, left panels) was likely the result of
the considerably reduced numbers of NPCs and
immature neuron populations at this age compared with those of
P10.Nonetheless,wedemonstrate that in adultmice theSyn-Cre
transgene can only elicit recombination in differentiated neurons,
while the hGFAP-Cre transgene affects both NPCs and neurons.
The effective ablation of TrkB with hGFAP-Cre was further dem-
onstrated by immunoblotting for TrkB in the hippocampus of
adult mice (Figure 2D), and by RT-PCR detection of TrkB
mRNA in FACS-isolated, Nestin-GFP-positive DG NPCs (Fig-
ure 2E). Therefore by utilizing these two different Cre transgenic
lines, differences between genetic ablation of the TrkB gene in
the granule layer of the DG and additional ablation in the SGZ
where progenitors reside can be studied.
Ablation of TrkB in Early Postnatal NPCs Impairs
DG Morphogenesis
The conditional knockout animals, carrying either the hGFAP-
Cre (TrkBhGFAP) or the Syn-Cre (TrkBSyn), are viable at birth and
have normal survival rates (up to 15 months recorded) (Luikart
et al., 2005). The TrkBhGFAP mice displayed a significant reduc-
tion in the volume of the DG granular layer (Figures 3A and 3B)
that first became measurable at P10. The volume reduction sta-
bilized at around 30% after the initial postnatal weeks and per-
sisted throughout adulthood. This abnormality was not caused
by changes in cell density or cell size (Figure 3D; p > 0.2), but
rather was a result of decrease in the number of granule neurons,
evidencedbyasignificant reduction in the thicknessof theDGgran-
ular layer (Figure 3C; n = 6 for each, F2,15 = 5.477, p = 0.0164).Neuron 59, 399–412, August 14, 2008 ª2008 Elsevier Inc. 401
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affected in the TrkBhGFAP mice (Figure S3 and not shown). The
reduction of volume was most prominently observed in the hip-
pocampus and DG, and did not appear to be a secondary result
of a broader developmental defect, because the TrkBhGFAP mice
had normal body and brain size at all ages examined (Figure S2).
We also measured the volumes of other anatomical regions,
such as the striatum, in 2-month-old TrkBhGFAP mice and found
normal volume (23.62 ± 0.94 mm3 in controls, 23.32 ± 1.06 mm3
Figure 3. Ablation of TrkB in Postnatal NPCs Impaired DG
Morphogenesis
(A) Representative images of Nissl-stained DG sections from control,
TrkBhGFAP, and TrkBSyn mice at P15. The decreases in DG size and gran-
ular layer thickness were only observed in TrkBhGFAP mice. Red lines and
circles highlight the length of the granular layer and the size of single cells,
respectively. Scale bars, 1 mm (hippocampus) and 10 mm (DG).
(B) Quantitative analysis revealed that the reduction in the DG volume
of TrkBhGFAP mice first became measurable at P10 and persisted in
adulthood. n > 7 for each.
(C) At P15, TrkBhGFAP mice, but not TrkBSyn mice, had thinner granular
layer, demonstrated by a decrease in neuronal number. Data is shown
as percentage of control. n = 6 for each. F2,15 = 5.477, p = 0.0164. GL,
granular layer.
(D) Comparative analysis of the size and density of DG granular neurons
from control and TrkBhGFAP mice. Note the absence of difference in either
category.
(E) DAPI staining of hippocampus sections from control and BDNFhGFAP
mice at the age of 2 months. Note the decrease in DG size in the
BDNFhGFAP mice. Scale bar, 200 mm.
(F) Quantitative analysis revealed a 30% reduction in DG volume in the
BDNFhGFAP mice at the age of 2 months. n = 8–10 for each.
Results are mean + SEM. *p < 0.05, **p < 0.01.
in TrkBhGFAP, n = 6 for each, p > 0.2). The TrkBSyn animals,
contrary to the TrkBhGFAP mice, displayed normal develop-
ment of the DG granular layer (Figures 3A–3C). These obser-
vations demonstrate that TrkB expression in the SGZ is
required for the normal structural development of the
DG. The phenotypic difference between the TrkBhGFAP and
TrkBSyn mice suggests a cell-autonomous function of TrkB
in the DG NPCs. We have previously reported that condi-
tional deletion of BDNF using the hGFAP-Cre transgene
(BDNFhGFAP) resulted in 80% reduction of BDNF protein level
in the hippocampus (Monteggia et al., 2007); we note that
these mice also displayed significantly reduced DG granular
layer volume, indicating a ligand-receptor coincidence (Fig-
ures 3E and 3F, n = 8–10 for each genotype, p < 0.005).
Ablation of TrkB Impairs Proliferation
and Neurogenesis
Given the apparent reduction in the number of granule neu-
rons in TrkBhGFAP mice, but not TrkBSyn mice, we examined
whether lack of TrkB in the NPCs affected the neurogenic ca-
pacity of the SGZ. Control and TrkB mutant animals were
evaluated at P15, during a period in which the DG undergoes
dynamic morphogenesis (Altman and Bayer, 1990). The
number of NeuroD-positive, newly generated neurons was
drastically reduced in the TrkBhGFAP mice, whereas the num-
ber in TrkBSyn mice was comparable with that of the control
mice (Figure 4A). Thus, TrkB ablation in the NPCs, but not in
differentiated neurons, impairs hippocampal neurogenesis.
Reduced neurogenesis in the absence of TrkB could be
caused by increased cell death, decreased proliferation, or
a combination of both processes. We first examined pro-
grammed cell death using TdT-mediated dUTP nick end labeling
(TUNEL) assay and immunohistochemistry for activated caspase
3. At all time points examined, the number of apoptotic cells de-
tected with either method was uniformly low and no measurable402 Neuron 59, 399–412, August 14, 2008 ª2008 Elsevier Inc.
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lack of TrkB did not appreciably affect survival in vivo
(Figure S3; n = 6 for each, p > 0.2).
We next assessed proliferation by measuring the number of
cells that incorporate the DNA synthesis marker 5-bromo-20-de-
oxyuridine (BrdU). P15 mice were treated with pulses of BrdU
Figure 4. Lack of TrkB in NPCs Impaired Neurogenesis and Proliferation In Vivo and In Vitro
(A) Representative confocal images of the DG immunostained for NeuroD (red). Note the reduction of NeuroD-positive cells, representing immature neurons, in
TrkBhGFAP mice, but not TrkBSyn mice (P15). Scale bar, 100 mm.
(B and C) Proliferation in the DGwas decreased in TrkBhGFAPmice, but not TrkBSyn mice, evidenced by a reduction in Ki67-positive cells (C) or BrdU-positive cells
(B and C). Scale bar, 100 mm. n = 7–9 for each. F2,21 = 78.39, p < 0.0001 (BrdU); F2,21 = 51.64, p < 0.0001 (Ki67).
(D and E) Cell-cycle analysis using BrdU pulsing and coimmunostaining for BrdU (green) and Ki67 (red) showed an increase in the ratio of BrdU-labeled cells that
have exited the cell cycle (BrdU+Ki67) in the DG of TrkBhGFAP mice. Arrowheads indicate BrdU+Ki67 cells. Scale bar, 100 mm. Data represent the ratio of
(BrdU+Ki67)/(All BrdU-positive).
(F) Western blots of lysates fromDG-derived neurospheres probed for phospho-Trk490, TrkB, and actin, with andwithout BDNF stimulation. Note the abundance
of TrkB expression and the increase of phospho-Trk in the presence of BDNF.
(G) Cells from the DG of adult mice were plated at equal density and allowed to proliferate in the presence of EGF and bFGF. The frequency of neurosphere
formation was lower in the TrkBhGFAP mice, indicating a decrease in NPC population.
(H) Addition of BDNF facilitated the growth of primary neurospheres derived from the DG of control mice, but not of the TrkBhGFAP mice. TrkBhGFAP neurospheres
grown without BDNF were also smaller than control, indicating impaired proliferation. n = 4 for each. ANOVA revealed significant effects of BDNF (F1,12 = 6.994,
p = 0.0214), genotype (F1,12 = 102.2, p < 0.0001), and an interaction between the two (F1,12 = 19.3, p = 0.0009).
Results are mean + SEM. *p < 0.05, **p < 0.01, ***p < 0.001. Error bars, mean +SEM.Neuron 59, 399–412, August 14, 2008 ª2008 Elsevier Inc. 403
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compassing the inner granular layer and SGZ, the number of
BrdU-positive cells in the TrkBhGFAP mice displayed a 48% re-
duction compared with that of control mice (Figures 4B and
4C; n = 7–9 for each; F2,21 = 78.39, p < 0.0001; p < 0.001 for
post hoc test of control to TrkBhGFAP comparison). Similarly,
the number of cells positive for Ki67, an endogenous marker
for actively cycling cells, was decreased by 51% in the SGZ of
the TrkBhGFAP mice (Figures 4B and 4C; n = 7–9 for each; F2,21 =
51.64, p < 0.0001; p < 0.001 for post hoc test of control to
TrkBhGFAP comparison). Again, the numbers of BrdU- or Ki67-
positive cells were unaffected in the DG of the TrkBSyn mice (Fig-
ures 4B and 4C; p > 0.2 for control to TrkBSyn comparisons).
To further investigate the cellular abnormality that leads to the
significant decrease of proliferation in the TrkBhGFAP mice, we
evaluatedcell-cycle exit of BrdU-incorporatingcells by examining
their expression of Ki67 after a 2 hr chase period, at which point
cells thatwere labeledwithBrdUduring theSphasebut have sub-
sequently left the cycle would lose their Ki67 expression (BrdU+;
Ki67), whereas the ones that remained in active cell cycle would
be double positive (BrdU+;Ki67+). In the TrkBhGFAPmice 23.1%±
3.9 % of all BrdU-positive cells were Ki67-negative, displaying
a 208% increase in cell-cycle exit over the control mice, where
only 7.5% ± 1.3 % were Ki67-negative (Figures 4D and 4E; 1053
BrdU-positive cells fromfive control, and772 fromfiveTrkBhGFAP,
p < 0.05). Collectively, these observations demonstrate that TrkB
is required for normal precursor proliferation in the hippocampus.
Activation of TrkB in Response to BDNF Facilitates
Proliferation In Vitro
Our finding that the TrkBhGFAP mice, but not the TrkBSyn mice,
displayed impaired hippocampal neurogenesis suggested
a cell-autonomous requirement for TrkB in NPCs. To further ex-
amine their intrinsic properties, we cultured NPCs from the DG in
serum-free conditions. In the presence of epidermal growth fac-
tor (EGF) and basic fibroblast growth factor (bFGF), DG NPCs
formed neurospheres, which expressed TrkB receptor that could
be activated by exogenous BDNF (Figure 4F). Although main-
taining adult-DG-derived primary neurospheres in media con-
taining BDNF (50 ng/ml) for 7–10 days did not increase the
frequency of primary neurosphere formation (not shown), there
was a significant increase in the size of the neurospheres, sug-
gesting that activation of TrkB facilitates the expansion of neuro-
sphere-forming cells (Figure 4H; n = 4 for each group, p < 0.05 for
post hoc test with or without BDNF comparison in control cells).
Primary neurospheres derived from the DG of adult TrkBhGFAP
mice, when plated at equal density, displayed reduction in
both the number (Figure 4G; n = 4 for each group, p < 0.005)
and size (Figure 4H; p < 0.005 for post hoc test of control to
TrkBhGFAP comparison without BDNF; F1,12 = 102.2, p < 0.0001
for genotype; F1,12 = 6.994, p = 0.0214 for BDNF). The ability of
primary neurospheres to form secondary neurospheres was
also impaired in the TrkBhGFAP mice (secondary-to-primary neu-
rosphere ratio: 0.322 ± 0.058 in TrkBhGFAP and 0.843 ± 0.096 in
control, n = 4 for each, p < 0.005). In addition, deletion of TrkB
abolished neurosphere sensitivity to BDNF stimulation
(Figure 4H, p > 0.2). Using an Annexin V labeling assay, we exam-
ined the percentage of apoptotic cells in the neurosphere cul-404 Neuron 59, 399–412, August 14, 2008 ª2008 Elsevier Inc.tures and did not observe significant differences between control
and TrkBhGFAP cells with or without BDNF treatment (n = 4 for
each; with 50 ng/ml BDNF: 14.95% ± 1.38% in controls,
16.25% ± 2.65% in TrkBhGFAP; without BDNF: 14.46% ±
1.62% in controls, 17.69% ± 2.56% in TrkBhGFAP; F1,8 = 1.136,
p = 0.3177 for genotype; F1,8 = 0.0498, p = 0.8290 for BDNF),
suggesting that the reduction in the size of neurospheres derived
from TrkBhGFAP mice was not due to survival deficits. Thus,
BDNF facilitates proliferation by acting directly on NPCs, and
the activation of TrkB is solely responsible for this effect.
TrkB Is Required for Induced Proliferation
and Neurogenesis by ADs and Voluntary Exercise
Reduction in hippocampal volume has been observed in animal
models of stress (Coe et al., 2003; Czeh et al., 2001), which
may be reversed or prevented by chronic AD treatment (Sheline
et al., 2003). Similarly, reduction of hippocampal volume has
been reported in some studies of human patients with major de-
pression (Bremner et al., 2000; MacQueen et al., 2003) and post-
traumatic stress disorder (Gilbertson et al., 2002; Karl et al., 2006;
Smith, 2005). Although the cellular mechanism is unclear in hu-
mans, animal studies have demonstrated that chronic exposure
to various types of ADs induces DG proliferation and neurogene-
sis (Malberg et al., 2000), thereby potentially contributing to the
recovery of volume loss. In this context, we examined whether
chronic AD treatment can restore neurogenesis in TrkBhGFAP
mice. We thus treated control, TrkBhGFAP, and TrkBSyn mice
with daily injections of the serotonin reuptake inhibitor fluoxetine
(10 mg/g) or the tricyclic imipramine (20 mg/g) for 21 days (n = 7–29
for each group; see Table S1 available online). As previously es-
tablished, in thecontrolmice, bothdrugs increased thenumberof
Ki67-positive cells in the DG compared to saline (Figures 5A and
5B; F2,98 = 40.48, p < 0.0001 for treatment; p < 0.001 for post hoc
test of both AD-to-saline comparisons). The induction of prolifer-
ation was echoed by an increase in the number of newly gener-
ated neurons expressing Doublecortin and NeuroD (Figures 5C
and 5D and not shown; F2,98 = 30.79, p < 0.0001 for treatment;
p < 0.001 for post hoc test of both AD-to-saline comparisons).
In contrast, TrkBhGFAP mice treated with the same ADs did not
show an increase in the number of proliferating cells or immature
neurons (Figures 5A–5D; F2,98 = 332.3, p < 0.0001 for the effect of
genotype onKi67; F2,98 = 211.6, p< 0.0001onDoublecortin). This
treatment, or an extended 6week treatment, also failed to restore
the DG volume deficit in the TrkBhGFAP mice (not shown). The
TrkBSyn mice responded normally to both ADs (Figures 5A–5D;
p < 0.001 for post hoc test of both AD-to-saline comparisons).
In rodents, voluntary exercise such as wheel-running behavior
has been demonstrated to robustly induce neurogenesis, much
in the same fashion as AD treatment (van Praag et al., 1999). Less
is known, however, about the underlying mechanism of this
AD-like effect of exercise. To determine whether TrkB is also re-
quired for this process, we subjected control and TrkBhGFAP
mice to 6weeks of wheel-running (n = 8–16 for each group; Table
S2). Both the numbers of Ki67-positive and Doublecortin-posi-
tive cells increased in control runners, compared with control
sedentary animals (Figure 6C: F1,36 = 13.64, p = 0.0007 for exer-
cise; Figure 6D: F1,36 = 16.01, p = 0.0003; p < 0.001 for post hoc
test of both comparisons). A significant increase of BDNF protein
Neuron
TrkB Governs Sensitivity to AntidepressantsFigure 5. TrkB Expression in NPCs Was Required for Chronic-AD-Induced Proliferation and Neurogenesis
(A) Representative confocal images of immunostaining for Ki67 in the DG of saline- or fluoxetine-treated mice. Chronic treatment with fluoxetine increased the
number of proliferating cells (Ki67-positive) in the DG of control and TrkBSyn mice, but not of TrkBhGFAP mice. Scale bar, 100 mm. Sal, saline; Flx, fluoxetine.
(B) Quantitative analysis of Ki67-positive cells demonstrated lack of increases in the TrkBhGFAP mice after fluoxetine or imipramine treatment. Note the lower
number of Ki67-positive cells in the TrkBhGFAP mice with either saline or AD treatment, indicating impairment in proliferation at both basal and stimulated level.
n = 7–25 for each. ANOVA (generalized linear model [GLM]) found significant effects of AD treatment (F2.98 = 40.48, p < 0.0001), genotype (F2,98 = 332.3,
p < 0.0001), and the interaction of both (F2,98 = 19.64, p < 0.0001). Imi, imipramine.
(C) Chronic fluoxetine treatment increased the number of Doublecortin-positive cells (red) in the DG of control and TrkBSyn mice, but not TrkBhGFAP mice. Scale
bar, 10 mm.
(D) Fluoxetine and imipramine failed to elicit an increase in the number of immature neurons (Doublecortin-positive) in the TrkBhGFAP mice. n = 7–25 for each.
ANOVA (GLM) revealed significant effects of AD treatment (F2,98 = 30.79, p < 0.0001), genotype (F2,98 = 211.6, p < 0.0001), and the interaction between the
two (F2,98 = 5.471, p = 0.0005).
Results are mean + SEM. ***p < 0.001.level was also observed in the hippocampus of runners (66.44 ±
3.65 pg/mg in runners; 45.83 ± 2.99 pg/mg in sedentary controls;
n = 3 for each; p < 0.05). The TrkBhGFAPmice, despite normal run-
ning distance (5.96 ± 0.41 km/day in controls, 5.48 ± 0.34 km/
day in TrkBhGFAP, p > 0.2) as well as elevation of BDNF level in
runners (60.33 ± 4.43 pg/mg in runners; 40.94 ± 1.37 pg/ml in
sedentary controls; n = 3 for each; p < 0.05), did not show any
increase in proliferation and neurogenesis (Figures 6C and 6D,
p > 0.2 for both). Since we tested male and female mice in the
voluntary exercise paradigm, we further separated the results
into gender- and genotype-specific groups and found no statis-
tically significant difference between males and females of the
same genotype (not shown).
TrkB Is Required for Behavioral Improvement
Induced by ADs and Exercise
To determine whether the lack of neurogenic response in the
TrkBhGFAP mice was coupled with general insensitivity to chronic
ADsandexercise,we compared thedepression- andanxiety-likebehaviors in control and TrkBhGFAP mice. First, mice treated with
fluoxetine, imipramine, or saline for 21 dayswere examined in the
novelty-suppressed feeding test (NSFT), a conflict paradigm in
which the latency to feed in a novel environment is used as an
indicator of anxiety level (Santarelli et al., 2003). In agreement
with the general capacity of chronic ADs to ease anxiety, 24 hr af-
ter the last dose, control mice receiving fluoxetine or imipramine
displayed significantly shorter latency to feed compared with sa-
line-treated control mice (Figure 6A: F2,100 = 8.022, p = 0.0006 for
treatment; p < 0.001 for post hoc test for both AD-to-saline com-
parisons). The TrkBhGFAP mice, on the contrary, were insensitive
to the effects of either AD (Figure 6A: F2,100 = 10.49, p < 0.0001
for genotype). Similarly, TrkBhGFAP mice exposed to 6 weeks of
running showed no improvement in the NSFT, whereas the con-
trol runners displayed clear decrease in latency compared with
sedentary animals (Figure 6E: F1,41 = 15.09, p = 0.0004 for geno-
type; p < 0.05 for post hoc test of running effect in control mice).
No difference in home cage consumption or body weight loss
was observed across genotypes (not shown).Neuron 59, 399–412, August 14, 2008 ª2008 Elsevier Inc. 405
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TrkB Governs Sensitivity to AntidepressantsFigure 6. TrkBhGFAP Mice Were Insensitive to Chronic-AD- and Exercise-Induced Improvement in Depression- and Anxiety-like Behaviors
(A) In the novelty-suppressed feeding test (NSFT), chronic treatments with fluoxetine or imipramine shortened the latency to feed (indicating reduced anxiety) in
control and TrkBSyn mice, but not TrkBhGFAP mice. Data are shown as percentage of control with saline injection. n = 6–29 for each group. ANOVA (GLM) found
significant effects of AD treatment (F2,100 = 8.022, p = 0.0006) and genotype (F2,100 = 10.49, p < 0.0001).
(B) The tail-suspension test (TST) measured total duration of immobility (‘‘behavioral despair’’), which could be reduced by chronic fluoxetine or imipramine in
control and TrkBSyn mice, but not TrkBhGFAP mice. Data are shown as percentage of control with saline injection. n = 7–28 for each. ANOVA (GLM) revealed
significant effects of AD treatment (F2,100 = 4.233, p = 0.0172), genotype (F2,100 = 20.03, p < 0.0001), and the interaction of both (F2,100 = 5.085, p = 0.0009).
(C and D) Running for 6 weeks failed to increase the number of Ki67-positive (C) or Doublecortin-positive (D) cells in the DG of TrkBhGFAP mice. n = 6–13 for each.
ANOVA (GLM) revealed significant effects of running (F1,36 = 13.64, p = 0.0007 for Ki67; F1,36 = 16.01, p = 0.0003 for Doublecortin), genotype (F1,36 = 141.1,
p <0.0001 for Ki67; F1,36 = 58.46, p < 0.0001 for Doublecortin), and the interaction of the two (F1,36 = 12.66, p = 0.0010 for Ki67; F1,36 = 14.79, p = 0.0005 for
Doublecortin).
(E and F) TrkBhGFAP mice did not display decrease in latency to feed ([E], NSFT) or duration of immobility ([F], TST) after 6 weeks of running, compared with
sedentary controls. Data are shown as percentage of sedentary control. n = 8–16 for each. NSFT (F1,41 = 15.09, p = 0.0004 for genotype), TST (F1,41 = 9.082,
p = 0.0044 for genotype; F1,41 = 8.273, p = 0.0064 for exercise).
Results are mean + SEM. *p < 0.05, **p < 0.01, ***p < 0.001.Next we examined depression-like behavior in the control and
TrkBhGFAP mice by using the tail-suspension test (TST), a para-
digm of inescapable stress (Porsolt et al., 1987). All mice were
tested 48 hr after the last dose of AD or saline to exclude the
acute effects of AD on behaviors that do not correlate with prior
duration of drug treatment, or clinical responses. Control runners
and AD-treated control mice showed decreased immobility
(immobility being a state of ‘‘behavioral despair’’) compared
with sedentary or saline-treated control mice, respectively (Fig-
ure 6F: F1,41 = 9.082, p = 0.0044 for exercise, post hoc p <
0.01; Figure 6B: F2,100 = 20.03, p < 0.0001 for AD, post hoc p <
0.01 for fluoxetine, p < 0.001 for imipramine). The TrkBhGFAP
mice again failed to display any appreciable response to either
treatment (Figure 6B: F2,100 = 4.233, p = 0.0172 for genotype;
Figure 6F: F1,41 = 9.082, p = 0.0044 for genotype).
Despite the lack of response to ADs and exercise in the
behavioral paradigms of NSFT and TST, the saline-treated
TrkBhGFAP mice performed similarly compared to the control
mice, suggesting relatively normal depression- and anxiety-like
behaviors at the basal level. To further investigate this finding,
we examined a cohort of control and TrkBhGFAP mice in a series
of behavioral measures (Figure S5; n = 17–21 for each). We406 Neuron 59, 399–412, August 14, 2008 ª2008 Elsevier Inc.observed no significant differences within these two groups in
the dark-light test in either the length of time spent or activity in
the light compartment. In the open field test, the TrkBhGFAP
mice were equivalent to controls in the time spent in the center.
In the elevated-plus maze test, the TrkBhGFAP mice spent more
time in the open arm comparedwith littermate controls. Together
these results suggest normal (and in some cases reduced) base-
line anxiety-like behaviors in the TrkBhGFAP mice. Similarly, in the
forced swim test, the TrkBhGFAP mice displayed normal latency
to immobility, and a nonsignificant trend toward decreased total
length of immobility, thereby supporting earlier observations of
normal baseline depression-like behavior. Based on the above
observations, we conclude that the lack of response to ADs
and exercise in the TrkBhGFAP mice cannot be explained by alter-
ations in baseline behavior, but rather is a result of insensitivity to
the molecular and cellular changes induced by chronic ADs and
exercise.
Normal Sensitivity to Chronic ADs in Mice Lacking TrkB
in Differentiated Neurons
To explore whether the deficit in increased neurogenesis con-
tributed to the abolished behavior sensitivity to chronic ADs,
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TrkB Governs Sensitivity to Antidepressantswe tested the TrkBSyn mice in the TST and the NSFT. Similar to
control mice, upon chronic treatment with fluoxetine and imipra-
mine, the TrkBSyn mice showed significant decrease in anxiety
(Figure 6A; post hoc p < 0.05 for both ADs) and depression-
like behaviors (Figure 6B; post hoc p < 0.05 for both ADs). This
result, in conjunction with the observation that chronic AD treat-
ment increased DG proliferation and neurogenesis in these mice
(Figure 5), indicates that despite the lack of TrkB in differentiated
neurons, the unaffected TrkB signaling in the NPCs was suffi-
cient for the TrkBSyn mice to display a behavioral response to
chronic ADs.
Specific Ablation of TrkB in Adult NPCs Is Sufficient
to Block Sensitivity to ADs
To further delineate whether TrkB function in adult NPCs alone
was required for AD-induced neurogenic and behavioral re-
sponses, we utilized a tamoxifen-inducible form of Cre recombi-
nase, CreERT2, expressed under the regulatory element of the
Nestin gene, allowing for TrkB ablation specifically in the adult
neurogenic niches. When the Nestin-CreERT2 mice were inter-
bred with the R26 reporter mice (R26Nestin), Cre activity could
be visualized either in embryonic or in adult CNS in a tamoxi-
fen-dependentmanner. Specifically,when1-month-oldR26Nestin
mice were injected with vehicle or tamoxifen and analyzed 1
month afterward, spontaneous recombination (i.e., in vehicle-
treated mice) was minimal, while tamoxifen-induced recombina-
tion was restricted to the DG, subventricular zone (SVZ), rostral
migratory stream, olfactory bulb, and cerebellum (Figure 7A
and not shown). In the DG, recombination occurred specifically
in the inner granular layer and SGZ. To evaluate the efficiency
of Nestin-CreERT2 in targeting NPCs, we induced R26Nestin
mice at 1 month and analyzed them at 2 and 7 months of age.
The number of X-gal-stained cells was dramatically increased
in the 6months postinjection group, indicating effective recombi-
nation in the NPCs that were capable of proliferation and self-
renewal (Figure 7B). Additional confirmation was obtained by
double-immunostaining for b-gal and Doublecortin at 4 months
of age, where the majority of Doublecortin-positive cells also
coexpress b-gal (Figure 7C).
Asdescribed above,hGFAP-Cre-mediated ablation ofTrkB re-
sulted in a smaller DG that we attribute to the lack of TrkB signal-
ing in early postnatal NPCs, which sustains rapid proliferation
required for normal structural development. To bypass this
essential phase of DG postnatal morphogenesis, we subjected
TrkBflox/flox;Nestin-CreERT2 mice to tamoxifen (TrkBNestin) at
1 month of age. Littermate TrkBflox/flox;Nestin-CreERT2 mice in-
jected with vehicle, and TrkBflox/floxmice injected with tamoxifen,
were analyzed and collectively presented as the control group. At
the age of 6weeks and 3months, TrkBmRNAwas virtually unde-
tectable by RT-PCR in the DG NPCs of TrkBNestin mice using
FACS-sorted Nestin-GFP-positive cells (Figure 7D). TrkB protein
was also absent from the proliferating cells of the SGZ, while its
level in the majority of granular neurons was unaffected
(Figure 7E). As expected, ablation of TrkB at 1 month did not
lead to a reduction in DG granular layer volume when examined
at 3 months of age (Figure 7F: n = 6 for each; p > 0.2). Basal pro-
liferation in the SGZ at this age (as measured by Ki67 staining)
was modestly decreased in the TrkBNestin mice, whereas noaberrant cell death was observed (Figure S6). Upon exposure
to fluoxetine (10 mg/g) or imipramine (20 mg/g) for 21 days (n =
8–10 for each), the TrkBNestin mice did not display increased
NPC proliferation as measured by the numbers of Ki67-positive
cells (Figure 7G: F1,50 = 176.7, p < 0.0001 for genotype; F2,50 =
12.45, p < 0.0001 for treatment; F2,50 = 13.57, p < 0.0001 for inter-
action) and phosphorylated-histone-H3-positive cells (Figure S6;
F1,50 = 131.9, p < 0.0001 for genotype; F2,50 = 17.46, p < 0.0001
for treatment; F2,50 = 17.34, p < 0.0001 for interaction). The num-
ber of newly generated neurons as labeled by Doublecortin also
did not change in the TrkBNestin mice (Figure 7H: F1,50 = 141.9,
p < 0.0001 for genotype; F2,50 = 7.014, p = 0.0021 for treatment;
F2,50 = 12.56, p < 0.0001 for interaction). The absence of neuro-
genic response in the TrkBNestin mice coincided with a lack of be-
havioral improvements in both the NSFT (Figure 7I: F1,50 = 13.68,
p = 0.0005 for genotype) and the TST (Figure 7J: F1,50 = 18.15,
p < 0.0001 for genotype). These observations refine and confirm
the preceding studies, indicating that ablation of TrkB from
adult NPCs alone is sufficient to block sensitivity to chronic ADs.
DISCUSSION
Regulation of Postnatal and Adult
Neurogenesis in the DG
The identification of NPCs in the largely postmitotic adult brain
has transformed our perspective on the development, physiol-
ogy, and pathology of this organ. Anatomically, NPCs in the
postnatal and adult brain reside in the SVZ of the lateral ventricle
and the SGZ of the DG, regions considered to be residues of the
embryonic germinal niche (Alvarez-Buylla and Lim, 2004). How-
ever, adult NPCs, especially those in the DG, deviate from ‘‘em-
bryonic properties’’ and have been noted to possess limited self-
renewal, proliferation, and migration capacity (Bull and Bartlett,
2005; Seaberg and van der Kooy, 2002). Paradoxically, DG
NPCs gain a remarkable capacity to respond to various extrinsic
and intrinsic stimuli (Lledo et al., 2006; Ming and Song, 2005).
The signaling mechanisms that specify these unique properties
of DG NPCs, both on the basal level and the induced state, re-
main unidentified.
Our study shows that TrkB-expressing NPCs in the postnatal
and adult DG respond to BDNF. As demonstrated in the
TrkBhGFAP mice, ablation of TrkB from the DG NPCs blocked
BDNF-induced neurosphere growth in vitro, and impaired prolif-
eration and neurogenesis in vivo. Although the Cre-mediated
deletion of TrkB in the TrkBhGFAP mice was not restricted to DG
NPCs, the requirement for TrkB in proliferation was cell autono-
mous as evidenced by the facts that (1) neurospheres generated
from the DG of the TrkBhGFAP mice had impaired proliferation
in vitro; (2) in vivo, the dividing cells in the DG of the TrkBhGFAP
mice were more prone to prematurely exit the cell cycle; (3) pro-
liferation in the DG was unaffected in the TrkBSyn mice where
Cre-mediated recombination occurred exclusively in differenti-
ated neurons; and (4) temporal- and spatial-specific ablation of
TrkB in young adult NPCs (of TrkBNestin) also resulted in
impaired proliferation and neurogenesis.
Neurotrophic factors, particularly BDNF, have been shown to
promoteproliferation ofNPCs in vitro (Barnabe-Heider andMiller,
2003). Whether this effect resonates with a similar physiologicalNeuron 59, 399–412, August 14, 2008 ª2008 Elsevier Inc. 407
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(A) X-gal staining on sagittal brain sections of R26Nestin mice treated with vehicle or tamoxifen at 1 month and analyzed at 2 months of age.
(B) X-gal staining on DG sections of R26Nestin mice treated with tamoxifen at 1 month and analyzed 1 month or 6 months afterwards. Note the increase in
X-gal-stained cells 6 months after tamoxifen injection. Scale bar, 200 mm.
(C) Costaining for b-gal (green) and Doublecortin (red) on DG sections from R26Nestin mice treated with tamoxifen at 1 month and analyzed at 4 months of age.
Scale bar, 10 mm.
(D) RT-PCR detection of TrkB and G3PDH transcripts in FACS-sorted Nestin-GFP-positive and -negative cells from the DG of TrkBflox/flox;Nestin-CreERT2 mice
treated with tamoxifen (TrkBNestin) or vehicle (control) at 1 month old.
(E) Costaining for TrkB (green) and Ki67 (red) on DG sections from TrkBNestin mice at the age of 3 months (2 months posttamoxifen injection). Note the lack of
colocalization of TrkB and Ki67 in the SGZ. Scale bars, 10 mm and 5 mm.
(F) TrkBNestin mice at the age of 3 months had normal DG volume.
(G and H) Quantitative analysis revealed no increase in the number of Ki67-positive (G) or Doublecortin-positive (H) cells in the TrkBNestin mice after fluoxetine or
imipramine treatments. n = 8–10 for each. ANOVA (GLM) found significant effects of AD treatment (F2,50 = 12.45, p < 0.0001 for Ki67; F2,50 = 7.014, p = 0.0021 for
Doublecortin), genotype (F1,50 = 176.7, p < 0.0001 for Ki67; F1,50 = 141.9, p < 0.0001 for Doublecortin), and an interaction of the two (F2,50 = 13.57, p < 0.0001 for
Ki67; F2,50 = 12.56, p < 0.0001 for Doublecortin).
(I and J) TrkBNestin mice did not display decrease in latency to feed ([I], NSFT) or duration of immobility ([J], TST) after chronic exposure to fluoxetine or imipramine,
compared to control mice. Data are shown as percentage of control treated with saline. n = 8–10 for each. NSFT: F1,50 = 13.68, p = 0.0005 for genotype; F2,50 =
4.206, p = 0.0205 for the interaction of genotype and AD treatment. TST: F1,50 = 18.15, p < 0.0001 for genotype; F2,50 = 6.848, p = 0.0024 for AD and F2,50 = 9.488,
p = 0.0003 for an interaction of the two.
Results are mean + SEM. *p < 0.05, ***p < 0.001.requirement in vivo is less apparent. BDNF germline heterozy-
gous mice have been reported to have decreased (Lee et al.,
2000) or increased (Sairanen et al., 2005) proliferation, as well
as decreased (Sairanen et al., 2005) or normal (Rossi et al.,
2006). long-term neurogenesis. By directly ablating the BDNF re-
ceptor, TrkB, in NPCs, our data ascertain an unambiguous, cell-
autonomous requirement for TrkB inmaintainingproliferation and408 Neuron 59, 399–412, August 14, 2008 ª2008 Elsevier Inc.neurogenesis in theDG. It isworth noting that becauseTrkB is the
high-affinity receptor for both BDNF and neurotrophin 4 (NT4),
the phenotype observed in the TrkBhGFAP and TrkBNestin mice
could be a combinatory outcome of a lack of signaling response
to both ligands, although the expression level of NT4 in the post-
natal brain is lower than that of BDNF. We have examined the
BDNFhGFAP conditional mutant mice and observed a degree of
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TrkBhGFAP mice. NT4 null mice are viable (Liebl et al., 2000) and
appear to have normal DG volume (not shown).
The specific impairment of postnatal DG morphogenesis ob-
served in the TrkBhGFAP mice appears to be a unique phenome-
non. Although NPCs in the embryonic CNS express TrkB and
have been shown to benefit from exogenous BDNF in vitro (Bar-
nabe-Heider and Miller, 2003), ablation of TrkB or BDNF in vivo,
as demonstrated in TrkB and BDNF germline knockouts as well
as the TrkBhGFAP mice, does not result in aberrant neurogenesis
of the prenatal CNS. The TrkBhGFAP mice were born with, and
continued to have, normal brain size throughout adulthood. The
reduction of the DG granular layer volume was absent at birth,
and only becomes appreciable after P10. Absence of TrkB did
not affect proliferation in the primary dentate neuroepithelium at
E16.5, or the migration and resettling of the secondary dentate
matrix at P0 (not shown). Therefore, we reveal here a regulatory
mechanism that uncouples postnatal DG neurogenesis from em-
bryonic development. Interestingly, while early ablation of TrkB
(TrkBhGFAP) dramatically reducedproliferation in adultDG,weob-
served a more modest impairment in basal proliferation when
TrkB is removed at the young adult age (TrkBNestin). This likely re-
flects the combined effects of TrkB ablation in the early postnatal
periodon reducing individual cell division (bypromoting cell cycle
exiting) and diminishing the overall pool of progenitor cells avail-
able for proliferation. In contrast, late deletion of TrkB cannot
significantly disturb the progenitor pool size, and thus the pheno-
type in the TrkBNestin mice likely represents the role of TrkB in
regulating the behaviors of individual adult NPCs.
Our studies demonstrate that deletion of TrkB from DG NPCs
(TrkBhGFAP and TrkBNestin) abolishes the proliferative and neuro-
genic effects of chronic AD treatments and voluntary exercise.
This is consistent with earlier observations that both ADs and
running induce significant increases in BDNF level (Neeper
et al., 1996; Nibuya et al., 1995). The inability of TrkB null NPCs
to respond to ADs and running was most likely due to the lack
of sensitivity to BDNF, and not from developmental deficits
that compromise cell division, as evidenced by their capacity
to react to other exogenous factors including EGF, bFGF, and
oxygen conditions in vitro (not shown). Conversely, when TrkB
was ablated only from differentiated neurons (TrkBSyn), both
the proliferation and neurogenesis responses to chronic ADs
were maintained. It is intriguing that we observed a slightly
more robust response to ADs in the TrkBSyn mice, suggesting
that when surrounded by TrkB null neurons, NPCs and immature
neurons with unaffected TrkB signaling may have a selective
advantage in growth, survival, or both.
TrkB and the Behavioral Efficacy of ADs
There has been considerable evidence that genetic ablation of
BDNF or TrkBmay interfere with the normal function of the adult
brain, depending on the regions affected. Conditional knockout
animals lacking TrkB in forebrain neurons (with broader recombi-
nation than TrkBhGFAP and TrkBSyn) have impaired spatial learn-
ing behavior, but display normal anxiety level in the open field
test (Minichiello et al., 1999). The latter is consistent with our
observation that the TrkBhGFAP mice exhibited normal basal
anxiety-like behavior in the NSFT, the open field test, and thedark-light preference test. Likewise, the TrkBhGFAP mice seemed
to have normal depression-like behavior at the basal level, as
measured by the TST and the forced swim test. The TrkBNestin
mice only lack TrkB in a highly specific population of cells, and
were phenotypically indistinguishable from control mice at base-
line. Previous studies with BDNF mutants regarding these anxi-
ety- and depression-like behaviors have yielded mixed results:
some were normal (Gorski et al., 2003; Monteggia et al., 2004;
Saarelainen et al., 2003) while others were not (Chen et al.,
2006; Monteggia et al., 2007; Rios et al., 2001). This discrepancy
may be explained by the differences in the brain regions affected
by the genetic ablation. BDNF is a secreted protein that can be
transported and deposited across long distances in both retro-
grade and anterograde directions. Therefore, local inactivation
of the BDNF gene may well result in global disturbance of
BDNF protein level, thus confounding the interpretation of re-
sults. The recent discovery that BDNF in different regions of
the brain may have opposing functions in modulating the stress
response supports this notion (Berton et al., 2006).
Unlike control mice, the TrkBhGFAP (and TrkBNestin) mice were
insensitive to chronic ADs and exercise-induced improvement in
depression- and anxiety-like behaviors. This finding provides
compelling evidence that TrkB is required for a shared molecular
mechanism through which ADs and exercise act. This process is
likely to be BDNF dependent, echoing previous studies showing
elevated levels of BDNF with chronic ADs (Nibuya et al., 1995) as
well as blunted behavioral response to ADs in BDNFmutant an-
imals (Chen et al., 2006; Monteggia et al., 2004; Saarelainen
et al., 2003). Interestingly, TrkBSyn mice show normal behavioral
responses to chronic AD treatment, indicating that neuronal
expression of TrkB is not required for the behavioral efficacy of
ADs. Though the mechanism via which ADs elicit increase in
hippocampal BDNF level remains undefined, this process only
occurs after chronic exposure to ADs (Nibuya et al., 1995), impli-
cating BDNF elevation and the subsequent TrkB activation as an
indirect downstream event from the acute accumulation of
monoamine, such as serotonin and noradrenaline. It has been
suggested that chronic ADs promote the cAMP pathways and
increase CREB activity (Nibuya et al., 1996)—CREB being a tran-
scription factor that activates theBDNF gene, among amultitude
of other targets. While these observations provide important in-
sight into the molecular underpinning of AD response, future
work is needed to validate and further delineate the involvement
of this pathway in regulating neurogenesis and mood (Conti
et al., 2002; Nakagawa et al., 2002).
Functional Link between Neurogenesis
and Sensitivity to ADs
It has been debated whether neurogenesis in the adult hippo-
campus bears functional significance in the action of chronic
ADs, or the physiology of the hippocampus in general (Leuner
et al., 2006; Scharfman and Hen, 2007; Zhao et al., 2008). In
the current study, we selectively abolished the neurogenic sen-
sitivity and the corresponding behavioral responses to chronic
ADs by ablating TrkB in adult NPCs (TrkBNestin) and NPCs and
neurons (TrkBhGFAP), but not in neurons alone (TrkBSyn). There-
fore, we conclude that a TrkB-dependent increase in neurogen-
esis is required for the effects of chronic ADs in control andNeuron 59, 399–412, August 14, 2008 ª2008 Elsevier Inc. 409
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TrkB Governs Sensitivity to AntidepressantsTrkBSyn mice in behavioral paradigms of NFST and TST. The
hGFAP-Cre andNestin-CreERT2 transgenes elicit recombination
in the neurogenic niches of SVZ and hippocampus. However,
prior studies have excluded a possible link between SVZ neuro-
genesis and the behavioral effects of ADs in rodents (Malberg
et al., 2000; Santarelli et al., 2003). Thus, our data provide ge-
netic support and mechanistic insight to previous reports that ir-
radiation-mediated ablation of dividing cells from the hippocam-
pal region of rodents abolished their behavioral responses to
ADs (Airan et al., 2007; Santarelli et al., 2003; Wang et al.,
2008a). A recent study reports differential response to chronic
ADs in inbred strains of mice, suggesting differing molecular
and cellular mechanisms (Holick et al., 2008). Thus, in contrast
to the present findings and previous reports (Encinas et al.,
2006; Santarelli et al., 2003; Wang et al., 2008a), chronic fluoxe-
tine produces antidepressive behavioral effects in BALB/cJmice
by mechanisms independent of serotonin 1A receptor and DG
neurogenesis. This marked strain difference highlights the exis-
tence of multiple mechanisms by which chronic ADs change
anxiety- and depression-like behaviors, and raises the intriguing
possibility that genetic variations may be involved in determining
the path of AD efficacy.
Our results also suggest that reduced levels of basal prolifera-
tion in the DG of TrkBhGFAP and TrkBNestin mice do not directly
lead to obvious affective impairment, an observation consistent
with recent findings using an irradiation-mediated NPC ablation
method (Airan et al., 2007; Santarelli et al., 2003; Wang et al.,
2008a). Rather, these animal studies suggest ADs and exer-
cise-stimulated increase in DG neurogenesis may translate into
enhanced synaptic plasticity in the pertinent neural circuits
(Wang et al., 2008a), which subsequentlymanifests as behavioral
responsiveness to such treatments. One possible explanation for
this dissociation between basal and induced neurogenesis may
reside in functional differences between neurons generated at
the constant state and stimulated state (Jakubs et al., 2006).
The exact nature of these differences and the molecular mecha-
nism that encodes them remain to be determined. Nonetheless,
our data suggest that TrkB regulates DG NPCs in both states.
EXPERIMENTAL PROCEDURES
A detailed description of all procedures is included in the Supplemental Data.
Animals
The flox alleles of TrkB and BDNF were generated previously (Luikart et al.,
2005; Monteggia et al., 2007). All mouse protocols were approved by the Insti-
tutional Animal Care and Research Advisory Committee at University of Texas
Southwestern Medical Center.
Histology and Quantitative Analysis
Mice were intracardially perfused with PBS followed by 4% (w/v) paraformal-
dehyde (PFA) in PBS, and the dissected brains were postfixed in 4%PFA at 4.
In situ hybridization, TUNEL assay, X-gal, Nissl, and immunostaining were per-
formed as previously described (Lei et al., 2005; Luikart et al., 2005). Detailed
methods for these assays and the stereological quantifications are described
in Supplemental Experimental Procedures.
Protein Analysis
Total protein was extracted and measured for western blotting and BDNF
ELISA assay. Total protein from the supernatant was used for western blotting410 Neuron 59, 399–412, August 14, 2008 ª2008 Elsevier Inc.as described (Lush et al., 2008). BDNF level was measured using a BDNF
ELISA kit (Promega) as per manufacturer’s instructions.
Neurosphere Cultures
Neurosphere culture was established and maintained as described (Bull and
Bartlett, 2005) with some modifications. Briefly, DG of adult mice were dis-
sected (Seaberg and van der Kooy, 2002) and digested in 0.1% trypsin-
EDTA (Sigma) followed by mechanical trituration until smooth. Cells were
plated at a density of 20 cells/ml in complete growth medium consisting of
mouse NeuroCult NSC basal medium (StemCell Technologies), mouse Neuro-
Cult NSC proliferation supplements (StemCell Technologies), 2 mg/ml heparin
(Sigma), EGF (20 ng/ml, GIBCO), and bFGF (10 ng/ml, Sigma). Treatment with
BDNF (50 ng/ml, R&D Systems) started from the first day, or 30 min before
harvest in the case of phospho-Trk490 western blotting.
FACS
For FACS isolation of GFP-positive or -negative cells, primary cells were pre-
pared from the DG of Nestin-GFP transgenicmice at the ages of P2, P15, and 2
months by following the procedure for establishing neurosphere culture.
GFP-positive and -negative fractions of the live cells (propidium iodide nega-
tive cells) were analyzed and sorted on FACSAria.
Tamoxifen Treatment
Tamoxifen (Sigma) was dissolved in a sunflower oil/ethanol mixture (9:1) at
6.7 mg/ml. Vehicle (9:1 sunflower oil/ethanol) or tamoxifen was injected intra-
peritoneally to 1-month-old mice at 250 ml/20 g (0.83 mg/kg) twice a day for 5
consecutive days. All injected mice were observed daily for neurological-
related abnormality. TrkBflox/flox;Nestin-CreERT2 mice injected with vehicle
and TrkBflox/floxmice injected with tamoxifen were indistinguishable and there-
fore pooled as the control group.
AD Treatment, Voluntary Exercise, and Behavioral Tests
All animals used for AD treatment, running, and subsequent behavioral tests
were littermates. Detailed information on the cohorts of animals used and
the procedures of behavioral tests are described in Supplemental Data.
Briefly, immediately after the last dose of AD or saline, or the last day of run-
ning, mice were deprived of food for 24 hr and then subjected to the NSFT.
Twenty-four hours afterwards, the same groups of mice were subjected to
the TST. Latency to feed in the NSFT and length of immobility in the TST
were rated as previously described (Santarelli et al., 2003; Svenningsson
et al., 2006), with investigators blind to genotypes. Mice were sacrificed
24 hr after the TST for tissue collection and subsequent analyses.
SUPPLEMENTAL DATA
The Supplemental Data for this article include Supplemental Experimental Pro-
cedures, two tables, and six figures and can be found online at http://www.
neuron.org/cgi/content/full/59/3/399/DC1/.
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